TopoTarget A/S Release: New Drug Application For Belinostat In Relapsed Or Refractory PTCL Submitted To The FDA In The USA

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Topotarget announces the submission of a New Drug Application (NDA) for belinostat for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) to the US Food and Drug Administration (FDA). The NDA has been filed for Accelerated Approval with a request for Priority Review. Response from the FDA regarding acceptance to file is expected within 60 days from the FDA receipt date.

Help employers find you! Check out all the jobs and post your resume.

Back to news